Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
State-of-the-art evidence in the treatment of systemic sclerosis
JE Pope, CP Denton, SR Johnson… - Nature Reviews …, 2023 - nature.com
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …
Unmet medical needs in chronic, non-communicable inflammatory skin diseases
H Ujiie, D Rosmarin, MP Schön, S Ständer… - Frontiers in …, 2022 - frontiersin.org
An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Abstract Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder.
Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and …
Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and …
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
X Wang, X Wu, B Tan, L Zhu, Y Zhang, L Lin, Y **ao… - Cell, 2024 - cell.com
Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the
accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its …
accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Systemic sclerosis-associated interstitial lung disease
Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
AM Hoffmann-Vold, Y Allanore, M Alves… - Annals of the rheumatic …, 2021 - Elsevier
Objectives To identify overall disease course, progression patterns and risk factors
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …